Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas.

The oncologist - 1 Jan 2013

Raghav Kanwal P S, Shetty Aditya V, Kazmi Syed M A, Zhang Nianxiang, Morris Jeffrey, Taggart Melissa, Fournier Keith, Royal Richard, Mansfield Paul, Eng Cathy, Wolff Robert A, Overman Michael J

Abstract excerpt

UNLABELLED: Appendiceal adenocarcinomas (AAs) are rare and this has limited their molecular understanding. The purpose of our study was to characterize the molecular profile of AA and explore the role of targeted therapy against cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab
Share to Cyclooxygenase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microsatellite Instability

Share to Panitumumab

Share to Phosphatidylinositol 3-Kinases

Share to Pyrazoles

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 24149137
DOI: 10.1634/theoncologist.2013-0186
PMCID: PMC3868421

Genes

KRAS
EGFR
BRAF
KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24149137-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas.PMID 24149137Read ↗

Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer.Semantic proximity Read ↗

Uncovering molecular pathways in appendiceal cancer: A comprehensive characterization for precision oncology.Semantic proximity Read ↗

Molecular Characterization of Appendiceal Goblet Cell Carcinoid.Semantic proximity Read ↗

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestineSemantic proximity Read ↗

Genomic Landscape of Appendiceal NeoplasmsSemantic proximity Read ↗

Molecular Classification of Appendiceal Adenocarcinoma.Semantic proximity Read ↗

ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.Semantic proximity Read ↗

Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H MutationSemantic proximity Read ↗

Taxane-based Chemotherapy is Effective in Metastatic Appendiceal AdenocarcinomaSemantic proximity Read ↗

Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations.Semantic proximity Read ↗

Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms.Semantic proximity Read ↗

EGF receptor signaling affects bcl-2 family gene expression and apoptosis after massive small bowel resectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.